Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Bailleux

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Human Vaccines & Immunotherapeutics|September 20, 2018
Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccineAlain Bouckenooghe, Fabrice Bailleux, Emmanuel Feroldi
BMC Medical Research Methodology|December 29, 2015
Some extensions in continuous models for immunological correlates of protectionAndrew J Dunning, Jennifer Kensler, Laurent Coudeville, et al.
Human Vaccines|October 9, 2010
A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routesLaurent Coudeville, Philippe Andre, Fabrice Bailleux, et al.
BMC Medical Research Methodology|March 2, 2013
A threshold method for immunological correlates of protectionXuan Chen, Fabrice Bailleux, Kamal Desai, et al.
BMC Medical Research Methodology|March 10, 2010
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects modelLaurent Coudeville, Fabrice Bailleux, Benjamin Riche, et al.
The Pediatric Infectious Disease Journal|February 12, 2004
Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infantsRon Dagan, Helena Kayhty, Tomi Wuorimaa, et al.
Vaccine|August 25, 2005
Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccineTomi K Wuorimaa, Ron Dagan, Fabrice Bailleux, et al.
The Pediatric Infectious Disease Journal|August 17, 2002
Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccineSigurveig T Sigurdardottir, Gunnhildur Ingolfsdottir, Katrin Davidsdottir, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Human Vaccines & Immunotherapeutics|September 20, 2018
Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccineAlain Bouckenooghe, Fabrice Bailleux, Emmanuel Feroldi
BMC Medical Research Methodology|December 29, 2015
Some extensions in continuous models for immunological correlates of protectionAndrew J Dunning, Jennifer Kensler, Laurent Coudeville, et al.
Human Vaccines|October 9, 2010
A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routesLaurent Coudeville, Philippe Andre, Fabrice Bailleux, et al.
BMC Medical Research Methodology|March 2, 2013
A threshold method for immunological correlates of protectionXuan Chen, Fabrice Bailleux, Kamal Desai, et al.
BMC Medical Research Methodology|March 10, 2010
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects modelLaurent Coudeville, Fabrice Bailleux, Benjamin Riche, et al.
The Pediatric Infectious Disease Journal|February 12, 2004
Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infantsRon Dagan, Helena Kayhty, Tomi Wuorimaa, et al.
Vaccine|August 25, 2005
Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccineTomi K Wuorimaa, Ron Dagan, Fabrice Bailleux, et al.
The Pediatric Infectious Disease Journal|August 17, 2002
Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccineSigurveig T Sigurdardottir, Gunnhildur Ingolfsdottir, Katrin Davidsdottir, et al.
Human Immunology|October 12, 2021
Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in ThailandRasmi Thomas, Danaya Chansinghakul, Kriengsak Limkittikul, et al.
Pageof 1